Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of fulvestrant (Qingkeyi) in hormone receptor-positive advanced breast cancer
ChiCTR2100046365Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fulvestrant in breast cancer, sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Progression-free survival time. Started Jun 2021; status: recruiting.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100046365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046365.